• Home
  • Press
  • FCS Cancer 360-Plus Magazine: Sparing Breast Cancer Patients From Chemotherapy

FCS Cancer 360-Plus Magazine: Sparing Breast Cancer Patients From Chemotherapy

By The CCM Team

FCS TailorxSpreadNearly 70 percent of the women with early stage breast cancer, and an intermediate risk of its recurrence, who are currently receiving chemotherapy after surgery do not need it, according to a major international research study called the Trial Assigning Individualized Options for Treatment (TAILORx).

The study is good news for the nearly 260,000 women in the United States expected to be diagnosed with the disease this year. 

Learn more about the TAILORx study and other strategic storytelling from Florida Cancer Specialists, the nation’s largest independent oncology/hematology practice, in our current edition of FCS Cancer 360-Plus magazine.
Consonant Custom Media

NYC

Mike Eisgrau
Dir. of Business Development

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tampa Bay

(World Headquarters)
941-309-5380
Steve Smith
Publisher | Creative Director 

Contact Us

CA

John Wark
Consulting Editor | Dir. of Business Development

This email address is being protected from spambots. You need JavaScript enabled to view it.